CSL-Behring conducting stroke clinical trial

2nd August 2012

Stroke is among the three leading causes of death worldwide and the most frequent cause of permanent disability. Our paper in 2007 (reference below) suggested that Immunoglobulin given intravenously to mice could protect the brain against experimental stroke by preventing complement-mediated neuronal cell death. That study is now being translated into human volunteers in a clinical trial starting this week.

Arumugam, T.V.; Tang, S.-C.; Lathia, J. D.; Cheng, A.; Mughal, M. R.;Chigurupati,S.; Magnus, T.; Chan, S.L.; Jo, D-G.; Ouyang, X.; Fairlie, D.P.; Granger, D. N.; Vortmeyer, A.; Basta, M.; Mattson, M.P. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl. Acad. Sci. (USA)  2007104, 14104-14109.

 

http://clinicaltrials.gov/ct2/show/NCT01628055

Fairlie Group Home Page: http://fairlie.imb.uq.edu.au

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s